Literature DB >> 11419178

Gamma/delta T cells provide innate immunity against renal cell carcinoma.

H Kobayashi1, Y Tanaka, J Yagi, H Toma, T Uchiyama.   

Abstract

Host immune function plays a certain role against the development of renal cell carcinomas (RCCs), but the mechanism is not entirely understood. Human gamma/delta (gamma/delta) T cells defend the body against infection. In this study, we clarify the role of gamma/delta T cells in the surveillance system against RCCs by analyzing the gamma/delta T cells in peripheral blood mononucleocytes (PBMs) and tumor infiltrating lymphocytes (TILs) from 41 patients with RCCs. The results showed that the number of gamma/delta T cells expressing V gamma 2 and V delta 2 in variable elements of TCR was elevated in the PBMs in 10 patients, but not in any of 32 healthy individuals. The proportion of patients with an elevated number of gamma/delta T cells (> 10%) increased with cancer stage. The level of the gamma/delta T cells decreased after surgery. The gamma/delta T cells in the TILs were more activated than those in the PBMs. Evaluation of the junctional diversity of TCR V gamma 2 and V delta 2 chains showed that the increased peripheral blood gamma/delta T cells were oligoclonal rather than polyclonal. Taken together, our findings suggest that gamma/delta T cells recognize certain RCC-related antigens and play a role in the surveillance system against RCCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11419178     DOI: 10.1007/s002620100173

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

3.  Innate-like gammadelta T cell responses to mycobacterium Bacille Calmette-Guerin using the public V gamma 2 repertoire in Macaca fascicularis.

Authors:  Cristiana Cairo; Andrew M Hebbeler; Nadia Propp; Joseph L Bryant; Vittorio Colizzi; C David Pauza
Journal:  Tuberculosis (Edinb)       Date:  2007-02-09       Impact factor: 3.131

4.  Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR.

Authors:  G Blank; C Welker; J Haarer; M Sterk; S Nadalin; V A C Yañez; T O Joos; A Menrad; D Snell; G LaCorcia; A Königsrainer; R Handgretinger; K Schilbach
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

5.  Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

Authors:  Joshua M Lang; Mahazarin R Kaikobad; Marianne Wallace; Mary Jane Staab; Dorothea L Horvath; George Wilding; Glenn Liu; Jens C Eickhoff; Douglas G McNeel; Miroslav Malkovsky
Journal:  Cancer Immunol Immunother       Date:  2011-06-07       Impact factor: 6.968

6.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors:  Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal:  Clin Genitourin Cancer       Date:  2013-07-05       Impact factor: 2.872

7.  Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice.

Authors:  Saori Nakagawa; Koji Kushiya; Ikue Taneike; Ken'ichi Imanishi; Takehiko Uchiyama; Tatsuo Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

8.  Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.

Authors:  Brant A Inman; Xavier Frigola; Kimberley J Harris; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

Review 10.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.